1. Safety of Zilver PTX Drug-Eluting Stent Implantation Following Drug-Coated Balloon Dilation in a Healthy Swine Model
- Author
-
Maria Romero, Brandt Young, Kazuyuki Yahagi, Renu Virmani, Emanuel Harari, Anthony Ragheb, Frank D. Kolodgie, Aloke V. Finn, Hiroyoshi Mori, and Sho Torii
- Subjects
medicine.medical_specialty ,Drug coated balloon ,Time Factors ,Swine ,medicine.medical_treatment ,Constriction, Pathologic ,030204 cardiovascular system & hematology ,Balloon ,Prosthesis Design ,Iliac Artery ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Animal model ,Coated Materials, Biocompatible ,Angioplasty ,medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,business.industry ,Cardiovascular Agents ,Drug-Eluting Stents ,Surgery ,Femoral Artery ,Drug-eluting stent ,Models, Animal ,Dilation (morphology) ,Swine, Miniature ,Cardiology and Cardiovascular Medicine ,business ,Angioplasty, Balloon ,Vascular Access Devices - Abstract
Purpose: To compare the safety of Zilver PTX drug-eluting stents (DES) following drug-coated balloon (DCB) angioplasty or conventional balloon angioplasty (BA) in a healthy porcine iliofemoral artery model. Methods: DES implantation following DCB (DCB+DES) or BA (BA+DES) was assessed by angiography and histology in the nondiseased iliofemoral arteries of 20 animals, with sacrifice at 1, 3, and 6 months. Safety assessment compared quantitative measures of vessel integrity (eg, preservation of artery geometry, structure, and lumen dimensions; absence of aneurysm; malapposition) and histological parameters (eg, excessive inflammation). The percentage of uncovered struts could not be >30% per section and the endothelial cell loss had to be
- Published
- 2017